PrimeMovers informs and guide health care organizations, patient associations and life science industries through organizational and process changes to adopt best health care practices and collaborative approaches for problem solving. Clients seek our help to define their goals and processes and receive the advice, training and mentoring necessary to achieve actual, successful results from their change. We tailor the specific scope and goals of our work and implement those plans collaboratively with our clients. Examples include:

  • Collaborative Problem Solving For Health Care Systems e.g.
    • Shaping a Collaborative Environment;
    • Implementing Best Practices;
    • Establishing a Health Technology Assessment Function;
    • Establishing a Protocol for Crafting Managed Entry Agreements;
    • Advising on elements of Performance Measurement to maximize Health Gain and Optimise Resources.
  • Collaborative Change Management for Governments e.g.
    • Appropriate Best Practices;
    • Integrate Collaborative Negotiation Process;
    • Consult Key Stakeholder Perspectives on Health Care;
    • Optimize Pricing and Reimbursement Regulation;
    • Align the Leadership Around Key Policies and Initiatives;
    • Re-think Value Assessment and the Dimensions that Measure it;
    • Build Capacity to Drive Change and Equip with New Skills
    • Establish Protocols for 
    • Leadership Alignment
    • Granting Marketing Approval for Life Science Innovation 
    • Conducting Health Technology Assessments
    • Deciding Pricing and Reimbursement
    • Providing Financing and Defining Coverage
  • Collaborative Change Management for Life Science Industry
    • Integrate Collaborative Negotiation as a Standard Organization-Wide Process;
    • Align Directors and Senior Management Around Highest Priority Decisions;
    • Factor Key Stakeholder Perspectives on Health Care Into Important Corporate Decisions and Actions;
    • Achieve Prompt and Fair Market Access for Innovation;
    • Advocate for Fair Pricing and Reimbursement;
    • Advance Health Economics to Improve Health Technology Assessments;
    • Develop Persuasive Evidence That Proves the Value of Innovation;
    • Craft Effective Managed Entry Agreements to Provide Patient Access and Avoid Bad Precedent;
  • Advancing Knowledge, Dialogue, and Policy in the Pharmaceutical Industry 

    More

  • Open and well-informed communication on complex and often sensitive issues in the pharmaceutical sector is essential. It helps to identify blind spots within the system and stimulates constructive debate on urgently needed changes. By shedding light on challenging regulatory and economic questions, such dialogue increases transparency and encourages critical reflection on established practices.
  • Importantly, it also creates momentum for innovative solutions and supports the development of sustainable, forward-looking frameworks that balance scientific progress with patient access and societal needs.

Latest Publications:

  • 26_03_Primemover: Konzept zur Erstellung eines Joint Clinical Assessment (JCA) Dossiers

Das 2025 eingeführte JCA ist Teil der EU-HTAR und soll Doppelarbeiten zwischen Mitgliedstaaten vermeiden sowie den Zugang zu innovativen Technologien beschleunigen. Ein erfolgreiches JCA-Dossier unterscheidet sich von klassischen HTA-Dossiers durch seinen starken Focus auf standardisierte klinische Evidenz und die Bewertung der relativen Wirksamkeit auf europäischer Ebene.

2603_Primemover_Konzept zur Erstellung eines Joint Clinical Assessment (JCA) Dossiers

  • 26_03_Primemover: Preparing for the European Joint Clinical Assessment (JCA)

The key question is no longer how to prepare a dossier—but how to build an organisation capable of delivering it. Companies that recognise this shift early will be best positioned to navigate the new environment successfully.

2603_Primemover_Preparing for the European Joint Clinical Assessment (JCA)

  • 25_03_Primemover: A Briefing Paper on EU-HTA Regulation: Harmonization or Redundance

The EU-HTAR simplifies clinical evaluation by reducing redundant work and establishing uniform procedures. However, some bureaucratic elements remain, such as economic consideration and reimbursement decisions.

2503_PrimemoverA Briefing Paper on EU-HTA Regulation

  • 25_03_Primemover: Rethinking Market Access Strategies for Innovative Medical Technologies

Healthcare landscape has shifted towards the growing influence of payers and HTA bodies as gatekeepers of market access. Innovative technologies must demonstrate not only clinical efficacy, but also clear value for money. To remind resilient in this new environment, companies should redesign their operating models to create, demonstrate, and sustain value.

2503_Primemover_Rethinking Market Access Strategies for Innovative Medical Technologies

  • 25_01_Primemover: Moving from a “single price mechanism” to an “indication-based mechanism”: Quo vadis?

Innovative therapies offer high value but create economic pressure on healthcare systems, when used across multiple indications. IBP aims to align prices with value per indication, yet its real-world application, impact, and challenges remain insufficiently understood.

2501_Primemover_Moving from a single price mechanism to an indication-based mechanism

  • 25_06_Primemover: Was ist ein fairer Preis für CAR-T-Zelltherapien?

CAR-T Zelltherapien revolutionieren die Krebsbehandlung stellt aber wegen ihrer extrem hohen Kosten und begrenzten Bewertungsmodelle Gesundheitssysteme vor grosse ökonomische und ethische Herausforderungen.

2506_Primemover_Was ist ein fairer Preis für CAR-T-Zelltherapien

  • 26_01_Primemover: Therapie im Vorsprung, Politik im Dilemma

Nicht-genbasierte Gentherapien für chronische Erkrankungen markieren einen Paradigmenwechsel hin zu nachhaltiger Krankheitskontrolle, treffen jedoch auf Gesundheitssysteme, die weiterhin auf kurzfristige Budgets und inkrementelle Innovationen ausgerichtet sind.
Das zentrale Problem ist politisch-systemisch: Neue Therapien werden regulatorisch und ökonomisch fehlbewertet, wodurch ihr langfristiger Nutzen unterschätzt und Innovation strukturell gebremst wird.
Ein konsistenter, wertorientierter Ordnungsrahmen für Bewertung, Preisbildung und Finanzierung ist entscheidend – denn die eigentliche Frage ist nicht, ob sich Gesundheitssysteme diese Therapien leisten können, sondern ob sie es sich leisten können, sie nicht zu integrieren.

2601_Primemover_Therapie im Vorsprung, Politik im Dilemma

  • 25_03_Primemover: Wachstumsmarkt Krebs – Neuartige & hochinnovative Ansätze in der Forschung

Der wachsende «Werkzeugkasten» der Onkologie bietet zunehmend personalisierte und gezielte Behandlungen. Besonders das Feld der ziel gerichteten Technologien, deren Behandlung auf dem genetischen Profil des Tumors, nicht auf dessen Standard basierten, bietet vielversprechende Ansätze. Nötig sind neue, nutzenbasierte und indikationsspezifische Preis- und Erstattungsmodelle sowie koordinierte, transparente Aushandlungsprozesse, um ein nachhaltige -und gerechte Finanzierung sicherzustellen.

2503_Primemover_Wachstumsmarkt Krebs – Neuartige & hochinnovative Ansätze pdf

  • Moving from a “single price mechanism” to an “indication-based mechanism”: Quo vadis? by Dr. Peter Lauper/January

  • Collaborative Value Management for Life Sciences Industry

  • Make the right value choice early on in the development process
  • Include systematically HTA & payer perspective on value in early development
  • Generate evidence-based and differentiated Value Proposition
  • Include HTA & Payer perspective through rigorous integration in the development
  • Apply state of the art techniques of economic evaluation to generate the information required to inform resource allocation decisions
  • Pro-actively and consistently communication the value proposition to internal and external stakeholders to stimulate a value focus